ACST News and Press, Acasti Pharma Inc. From 11/24/21

LAVAL, Québec, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and CEO of Acasti Pharma, will be participating in the Benzinga All Access eve...

Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...

LAVAL, Québec, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced the annual grant of stock options to its employees, executives and directors. An aggregate of 2,077,900 opti...

Laval, Quebec--(Newsfile Corp. - November 11, 2021) - Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) ("Acasti" or the "Company"), today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021. Jan D'A...

Acasti Pharma Inc. (ACST) Q3 2021 Results Conference Call November 10, 2021 4:30 PM ET Company Participants Jan D’Alvise – President and Chief Executive Officer Pierre Lemieux – Chief Operating Officer, Canada, Chief Scientific Officer, and Co-Founder George Kottayil ...

Acasti Pharma (NASDAQ:ACST): FQ2 GAAP EPS of $0.03 beats by $0.60. As of September 30, 2021, Acasti had $50.8 million of cash, cash equivalents and short-term investments.  Press Release For further details see: Acasti Pharma EPS beats by $0.60

LAVAL, Québec, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced its operating and financial results for the second quarter of fiscal 2022 ended Sep...

Acasti Pharma (NASDAQ:ACST) is scheduled to announce Q2 earnings results on Wednesday, November 10th, before market open. The consensus EPS Estimate is -$0.57. For further details see: Acasti Pharma Q2 Earnings Preview

ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...

LAVAL, Quebec, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Wednesday, November 10, 2021 to discuss the Company ...